SOPHiA GENETICS (SOPH) CSO gets RSUs, options and corrects holdings
Filing Impact
Filing Sentiment
Form Type
4/A
Rhea-AI Filing Summary
SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu reported equity compensation grants and a correction to his reported holdings. He received a share option for 164,671 ordinary shares at an exercise price of $5.04 per share and a grant of 112,936 ordinary shares in the form of restricted stock units under the 2021 Equity Incentive Plan. The RSUs vest 25% on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030. The option vests 25% on April 2, 2027, then in equal monthly installments through April 2, 2030, and expires on April 2, 2036. The amendment corrects his beneficial ownership after the transactions to 650,052 ordinary shares, instead of 112,936 shares previously reported due to an inadvertent error.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Xu Zhenyu
Role
Chief Scientific Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Share Option (Right to Buy) | 164,671 | $0.00 | -- |
| Grant/Award | Ordinary Shares | 112,936 | $0.00 | -- |
Holdings After Transaction:
Share Option (Right to Buy) — 164,671 shares (Direct);
Ordinary Shares — 650,052 shares (Direct)
Footnotes (1)
- Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030. This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 112,936 ordinary shares due to an inadvertent error. The correct amount is 650,052 ordinary shares. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.
Key Figures
RSU grant: 112,936 ordinary shares
Option grant size: 164,671 ordinary shares
Option exercise price: $5.04 per share
+3 more
6 metrics
RSU grant
112,936 ordinary shares
Restricted stock units granted April 2, 2026
Option grant size
164,671 ordinary shares
Share option (right to buy) granted April 2, 2026
Option exercise price
$5.04 per share
Exercise price for share option
Option expiration
April 2, 2036
Expiration date of share option
RSU vesting start
April 2, 2027
25% of RSUs vest on this date
Corrected ownership
650,052 ordinary shares
Beneficially owned following transactions
Key Terms
restricted stock unit ("RSU"), 2021 Equity Incentive Plan, beneficially owned, vest, +1 more
5 terms
restricted stock unit ("RSU") financial
"Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan."
2021 Equity Incentive Plan financial
"Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan."
beneficially owned financial
"correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction)"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
vest financial
"25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
What insider transactions did SOPH Chief Scientific Officer Zhenyu Xu report on this Form 4/A?
Zhenyu Xu reported two equity compensation awards: a share option over 164,671 ordinary shares at an exercise price of $5.04, and a grant of 112,936 ordinary shares in restricted stock units, all dated April 2, 2026.
How do the RSUs granted to SOPH Chief Scientific Officer vest?
The 112,936 RSUs vest 25% on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030, conditioned on the executive’s continued service with SOPHiA GENETICS SA.
What correction does this Form 4/A make to prior SOPH insider ownership reporting?
The amendment corrects the amount of ordinary shares beneficially owned after the reported transactions. It revises Column 5 from 112,936 ordinary shares to the correct figure of 650,052 ordinary shares, fixing an inadvertent error in the earlier filing.